RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Pharmaceutical Industry

A collection of news and information related to Pharmaceutical Industry published by this site and its partners.

Top Pharmaceutical Industry Articles

Displaying items 23-33
  • Activist investor Bill Ackman wants auction for Allergan

    Activist investor Bill Ackman wants auction for Allergan
    Activist hedge fund manager Bill Ackman on Friday urged Botox maker Allergan Inc. to put itself up for auction. The request follows Allergan’s disclosure that it is in talks to potentially merge with a firm other than the Canadian company Ackman...
  • Allergan, fighting off Valeant, discussing merger with another firm

    Allergan, fighting off Valeant, discussing merger with another firm
    Botox maker Allergan Inc. said it’s discussing a merger with an unnamed firm as it battles a hostile takeover by Valeant Pharmaceuticals. For six months Irvine-based Allergan has fought off an unsolicited takeover bid from Valeant...
  • Zlati Meyer: Scams spread in wake of Ebola fears

    Hey, have I got a stock tip for you! It'll make you millions of dollars in no time. There's this drug company who's discovered a cure for Ebola ... Stop right there. It's a scam. Experts are warning the public not to fall for get-rich-quick schemes...
  • Hospira profit soars despite loss of drug exclusivity

    Hospira profit soars despite loss of drug exclusivity
    Lake Forest-based drugmaker Hospira's profit skyrocketed in the third quarter compared with the same period a year earlier, mainly because of the sale of its clinical surveillance software business, Theradoc. Net income rose to $158.6 million, or 92...
  • Elliott Associates may sue AbbVie over scuttled deal

    BOSTON (Reuters) - Hedge fund Elliott Associates may take legal action against pharmaceuticals company AbbVie Inc for scuttling a merger deal with Shire Plc. Elliott said in a quarterly letter to investors that it was disappointed when AbbVie's board...
  • OraSure expects milestones in its Ebola research

    OraSure expects milestones in its Ebola research
    By the end of the year, Bethlehem-based OraSure expects to announce key research milestones in determining if its OraQuick rapid in-home HIV test can be adapted to screen patients for Ebola. The company has consulted with the federal Food and Drug...
  • Ebola scams spreading as fears mount

    Ebola scams spreading as fears mount
    I can't tell you whether to believe assurances from those in power that the deadly Ebola virus will be kept in check, but there's no doubt that panicking can expose you to harm. Scams related to the Ebola outbreak are spreading and you aren't immune....
  • AbbVie says tax rule changes scuttled deal for Shire

     AbbVie says tax rule changes scuttled deal for Shire
    AbbVie is blaming the Obama administration for pulling the plug on its $55 billion proposed acquisition of Irish drugmaker Shire, asserting that the largest corporate deal of the year no longer made economic sense under new federal tax regulations. Late...
  • AbbVie board calls off Shire acquisition

    AbbVie board calls off Shire acquisition
    North Chicago-based drugmaker AbbVie has pulled the plug on its plan to buy Dublin-based Shire, recommending shareholders vote against the planned $55 billion takeover following new U.S. tax rules. Shire stands to be paid a break-up fee of about $1.64...
  • Magnetic stimulation gains in depression treatment

     Magnetic stimulation gains in depression treatment
    A machine that sends magnetic pulses into a patient's brain has become the new frontier of depression treatment, promising to ease symptoms for those who have found little relief from medication or talk therapy. The treatment, known as transcranial...
  • AbbVie reconsiders its option with Shire

     AbbVie reconsiders its option with Shire
    AbbVie's surprise announcement late Tuesday that it is having second thoughts about its proposed acquisition of Shire raises numerous questions about the future of the deal. The North Chicago-based drugmaker said its board of directors will take...